News

Peptech will acquire 100% of the issued shares in EvoGenix for A$0.15 cash and 0.5055 Peptech shares for each EvoGenix share held. The merged entity, to be renamed,

SPI-1620 is being developed as an adjunct to chemotherapy. The highly selective endothelin-B agonist has demonstrated in experimental animal models a transient and selective increase in blood flow

Rhein Minapharm, Cairo-based Minapharm’s biotechnology subsidiary, will exclusively market Elafin in Egypt, Middle Eastern and African countries. Proteo will receive an upfront payment, milestone-payments and royalties on net

Preliminary analysis of the study results indicates DOV 21,947 was safe and well-tolerated at the doses examined and produced a significant decline in plasma triglyceride levels. The company

US regulators reviewed the drugs after two clinical trials suggested that they increased the risk of heart attacks and cardiac death. Nexium and Prilosec are proton pump inhibitors

Researchers from the New England Research Institutes found that, while men using statins did indeed have lower blood levels of androgens such as testosterone, it was more likely

In a project sponsored by the European Science Foundation (ESF) and the European Heads of Research Councils (EuroHORCS), Dr Nynke Dekker and her team are trying to stop

The orphan drug designation that Increlex received for the authorized indication will provide 10 years of marketing exclusivity in the EU. As a result of this marketing authorization,

Health Canada recently granted Shire HGT regulatory approval for Elaprase, indicated for enzyme replacement therapy in patients with Hunter syndrome. Hunter syndrome is an X-linked recessive disorder caused